1.44

0.70% 0.01

Adc Therapeutics Sa (ADCT)

Overview News Price History Option Chain Discussions Forecast

Adc Therapeutics Sa stock is traded at $1.44, with a volume of 326.75K. It is up +0.70% in the last 24 hours and up +8.27% over the past month. ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Previous Close:

$1.43

Open:

$1.45

24h Volume:

326.75K

Relative Volume:

0.92

Market Cap:

$131.91M

Revenue:

$69.56M

Net Income/Loss:

$-240.05M

P/E Ratio:

-0.4881

EPS:

-2.95

Net Cash Flow:

$-121.90M

1W Performance:

+8.27%

1M Performance:

+8.27%

6M Performance:

-51.19%

1Y Performance:

-69.56%

1-Day Range:

$1.435

$1.485

1-Week Range:

$1.3505

$1.50

52-Week Range:

$1.05

$5.17

Adc Therapeutics Sa Stock (ADCT) Company Profile

Name

Adc Therapeutics Sa

Sector

Healthcare (1152)

Industry

Biotechnology (677)

Phone

41 21 653 02 00

Address

BIOPOLE, EPALINGES

Employee

263

Twitter

Next Earnings Date

2025-03-21

Latest SEC Filings

ADCT's Discussions on Twitter

Compare ADCT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADCT Adc Therapeutics Sa	1.44	131.91M	69.56M	-240.05M	-121.90M	-2.95
VRTX Vertex Pharmaceuticals Inc	501.15	126.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	605.61	65.06B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	649.67	37.54B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	259.39	32.56B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	255.77	26.40B	3.81B	-644.79M	-669.77M	-6.24

Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-08-24	Initiated	Stephens	Overweight
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-06-22	Initiated	CapitalOne	Overweight
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral
Sep-21-22	Initiated	JP Morgan	Overweight
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-21	Initiated	Wolfe Research	Outperform
Aug-17-21	Resumed	Jefferies	Buy
Aug-09-21	Initiated	RBC Capital Mkts	Outperform
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight
Dec-03-20	Initiated	Stifel	Hold
Oct-29-20	Initiated	H.C. Wainwright	Buy
Jun-09-20	Initiated	BofA/Merrill	Buy
Jun-09-20	Initiated	Cowen	Outperform

View All

Adc Therapeutics Sa Stock (ADCT) Latest News

05:17 AM

ADC Therapeutics (ADCT) to Release Quarterly Earnings on Monday - Defense World

05:17 AM

May 02, 2025

LPL Financial LLC Invests $50,000 in ADC Therapeutics SA (NYSE:ADCT) - Defense World

May 02, 2025

May 01, 2025

Geode Capital Management LLC Acquires 9,938 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World

Apr 30, 2025

Apr 28, 2025

ADC Therapeutics (ADCT) Unveils Promising Preclinical ADC Data a - GuruFocus

Apr 28, 2025

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025 - BioSpace

Apr 28, 2025

Stock Market Recap: Adc Therapeutics SA (ADCT) Concludes at 1.41, a -5.37 Surge/Decline - DWinneX

Apr 28, 2025